Skip to main content
PMC home page
Infection and Immunity logoLink to Infection and Immunity
. 1997 Jul;65(7):2509–2516. doi: 10.1128/iai.65.7.2509-2516.1997

Localization of intravenously administered verocytotoxins (Shiga-like toxins) 1 and 2 in rabbits immunized with homologous and heterologous toxoids and toxin subunits.

M Bielaszewska 1, I Clarke 1, M A Karmali 1, M Petric 1
PMCID: PMC175354  PMID: 9199412

Abstract

Rabbits challenged intravenously with Shiga toxin or with Escherichia coli verocytotoxin 1 or 2 (VT1 or VT2) are known to develop diarrhea, paralysis, and death, which can be prevented by immunization with a toxoid. The pathological effects of VT1 in the central nervous system and the gastrointestinal tract of unimmunized rabbits correlate with the localization of 125I-VT1 in these tissues, whereas in immunized animals, localization of 125I-VT1 in target tissues is inhibited and labeled toxin is cleared by the liver and spleen. By using the approach described above in this study, rabbits immunized with VT1 toxoid, VT2 toxoid, or with the A or B subunit of each toxin were challenged with intravenous 125I-VT1 or 125I-VT2. After 2 h, the animals were sacrificed, and selected tissues were analyzed for uptake of labeled toxin. It was found that animals immunized with either VT1 toxoid or VT2 toxoid were protected from target tissue uptake of both 125I-VT1 and 125I-VT2. Rabbits immunized with either the VT1 A or VT2 A subunit were also protected from target tissue uptake of both the homologous and heterologous 125I-labeled holotoxins. In contrast, in animals immunized with the toxin B subunits, protection extended only against challenge by the homologous toxin. These results provide evidence of VT1 and VT2 cross-neutralization in vivo in the rabbit model and indicate that the in vivo cross-neutralization is a function, mainly, of antibodies directed to the VT A subunits. This suggests that the VT1 A or VT2 A subunit may be a suitable immunogen for immunizing humans against systemic VT-mediated disease.

Full Text

The Full Text of this article is available as a PDF (264.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Acheson D. W., Levine M. M., Kaper J. B., Keusch G. T. Protective immunity to Shiga-like toxin I following oral immunization with Shiga-like toxin I B-subunit-producing Vibrio cholerae CVD 103-HgR. Infect Immun. 1996 Jan;64(1):355–357. doi: 10.1128/iai.64.1.355-357.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Anderson L. J., Tsou C., Parker R. A., Chorba T. L., Wulff H., Tattersall P., Mortimer P. P. Detection of antibodies and antigens of human parvovirus B19 by enzyme-linked immunosorbent assay. J Clin Microbiol. 1986 Oct;24(4):522–526. doi: 10.1128/jcm.24.4.522-526.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Andreoli S. P., Bergstein J. M. Development of insulin-dependent diabetes mellitus during the hemolytic-uremic syndrome. J Pediatr. 1982 Apr;100(4):541–545. doi: 10.1016/s0022-3476(82)80749-x. [DOI] [PubMed] [Google Scholar]
  4. Arend W. P., Mannik M. Studies on antigen-antibody complexes. II. Quantification of tissue uptake of soluble complexes in normal and complement-depleted rabbits. J Immunol. 1971 Jul;107(1):63–75. [PubMed] [Google Scholar]
  5. BENACERRAF B., SEBESTYEN M., COOPER N. S. The clearance of antigen antibody complexes from the blood by the reticuloendothelial system. J Immunol. 1959 Feb;82(2):131–137. [PubMed] [Google Scholar]
  6. BRIDGWATER F. A., MORGAN R. S., ROWSON K. E., WRIGHT G. P. The neurotoxin of Shigella shigae: morphological and functional lesions produced in the central nervous system of rabbits. Br J Exp Pathol. 1955 Oct;36(5):447–453. [PMC free article] [PubMed] [Google Scholar]
  7. Barrett T. J., Potter M. E., Wachsmuth I. K. Continuous peritoneal infusion of Shiga-like toxin II (SLT II) as a model for SLT II-induced diseases. J Infect Dis. 1989 Apr;159(4):774–777. doi: 10.1093/infdis/159.4.774. [DOI] [PubMed] [Google Scholar]
  8. Boulanger J., Petric M., Lingwood C., Law H., Roscoe M., Karmali M. Neutralization receptor-based immunoassay for detection of neutralizing antibodies to Escherichia coli verocytotoxin 1. J Clin Microbiol. 1990 Dec;28(12):2830–2833. doi: 10.1128/jcm.28.12.2830-2833.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Burns J. C., Berman E. R., Fagre J. L., Shikes R. H., Lum G. M. Pancreatic islet cell necrosis: association with hemolytic-uremic syndrome. J Pediatr. 1982 Apr;100(4):582–584. doi: 10.1016/s0022-3476(82)80758-0. [DOI] [PubMed] [Google Scholar]
  10. CAVANAGH J. B., HOWARD J. G., WHITBY J. L. The neurotoxin of Shigella shigae; a comparative study of the effects produced in various laboratory animals. Br J Exp Pathol. 1956 Jun;37(3):272–278. [PMC free article] [PubMed] [Google Scholar]
  11. De Grandis S., Ginsberg J., Toone M., Climie S., Friesen J., Brunton J. Nucleotide sequence and promoter mapping of the Escherichia coli Shiga-like toxin operon of bacteriophage H-19B. J Bacteriol. 1987 Sep;169(9):4313–4319. doi: 10.1128/jb.169.9.4313-4319.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Downes F. P., Barrett T. J., Green J. H., Aloisio C. H., Spika J. S., Strockbine N. A., Wachsmuth I. K. Affinity purification and characterization of Shiga-like toxin II and production of toxin-specific monoclonal antibodies. Infect Immun. 1988 Aug;56(8):1926–1933. doi: 10.1128/iai.56.8.1926-1933.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Finbloom D. S., Plotz P. H. Studies of reticuloendothelial function in the mouse with model immune complexes. II. Serum clearance, tissue uptake, and reticuloendothelial saturation in NZB/W mice. J Immunol. 1979 Oct;123(4):1600–1603. [PMC free article] [PubMed] [Google Scholar]
  14. Fong J. S., de Chadarevian J. P., Kaplan B. S. Hemolytic-uremic syndrome. Current concepts and management. Pediatr Clin North Am. 1982 Aug;29(4):835–856. doi: 10.1016/s0031-3955(16)34216-x. [DOI] [PubMed] [Google Scholar]
  15. Griffin D. E., Gentry M. K., Brown J. E. Isolation and characterization of monoclonal antibodies to Shiga toxin. Infect Immun. 1983 Jul;41(1):430–433. doi: 10.1128/iai.41.1.430-433.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Griffin P. M., Tauxe R. V. The epidemiology of infections caused by Escherichia coli O157:H7, other enterohemorrhagic E. coli, and the associated hemolytic uremic syndrome. Epidemiol Rev. 1991;13:60–98. doi: 10.1093/oxfordjournals.epirev.a036079. [DOI] [PubMed] [Google Scholar]
  17. HOWARD J. G. Observations on the intoxication produced in mice and rabbits by the neurotoxin of Shigella shigae. Br J Exp Pathol. 1955 Oct;36(5):439–446. [PMC free article] [PubMed] [Google Scholar]
  18. Haakenstad A. O., Mannik M. The disappearance kinetics of soluble immune complexes prepared with reduced and alkylated antibodies and with intact antibodies in mice. Lab Invest. 1976 Sep;35(3):283–292. [PubMed] [Google Scholar]
  19. Harari I., Arnon R. Carboxy-terminal peptides from the B subunit of Shiga toxin induce a local and parenteral protective effect. Mol Immunol. 1990 Jul;27(7):613–621. doi: 10.1016/0161-5890(90)90003-i. [DOI] [PubMed] [Google Scholar]
  20. Harari I., Donohue-Rolfe A., Keusch G., Arnon R. Synthetic peptides of Shiga toxin B subunit induce antibodies which neutralize its biological activity. Infect Immun. 1988 Jun;56(6):1618–1624. doi: 10.1128/iai.56.6.1618-1624.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Karmali M. A. Infection by verocytotoxin-producing Escherichia coli. Clin Microbiol Rev. 1989 Jan;2(1):15–38. doi: 10.1128/cmr.2.1.15. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Karmali M. A., Petric M., Lim C., Fleming P. C., Arbus G. S., Lior H. The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. J Infect Dis. 1985 May;151(5):775–782. doi: 10.1093/infdis/151.5.775. [DOI] [PubMed] [Google Scholar]
  23. Karmali M. A., Petric M., Lim C., Fleming P. C., Steele B. T. Escherichia coli cytotoxin, haemolytic-uraemic syndrome, and haemorrhagic colitis. Lancet. 1983 Dec 3;2(8362):1299–1300. doi: 10.1016/s0140-6736(83)91167-4. [DOI] [PubMed] [Google Scholar]
  24. Karmali M. A., Petric M., Louie S., Cheung R. Antigenic heterogeneity of Escherichia coli verotoxins. Lancet. 1986 Jan 18;1(8473):164–165. doi: 10.1016/s0140-6736(86)92307-x. [DOI] [PubMed] [Google Scholar]
  25. Karmali M. A., Steele B. T., Petric M., Lim C. Sporadic cases of haemolytic-uraemic syndrome associated with faecal cytotoxin and cytotoxin-producing Escherichia coli in stools. Lancet. 1983 Mar 19;1(8325):619–620. doi: 10.1016/s0140-6736(83)91795-6. [DOI] [PubMed] [Google Scholar]
  26. Konowalchuk J., Dickie N., Stavric S., Speirs J. I. Properties of an Escherichia coli cytotoxin. Infect Immun. 1978 May;20(2):575–577. doi: 10.1128/iai.20.2.575-577.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Konowalchuk J., Speirs J. I., Stavric S. Vero response to a cytotoxin of Escherichia coli. Infect Immun. 1977 Dec;18(3):775–779. doi: 10.1128/iai.18.3.775-779.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Levin M., Walters M. D., Barratt T. M. Hemolytic uremic syndrome. Adv Pediatr Infect Dis. 1989;4:51–81. [PubMed] [Google Scholar]
  29. Lingwood C. A. Verotoxin-binding in human renal sections. Nephron. 1994;66(1):21–28. doi: 10.1159/000187761. [DOI] [PubMed] [Google Scholar]
  30. Loirat C., Sonsino E., Varga Moreno A., Pillion G., Mercier J. C., Beaufils F., Mathieu H. Hemolytic-uremic syndrome: an analysis of the natural history and prognostic features. Acta Paediatr Scand. 1984 Jul;73(4):505–514. doi: 10.1111/j.1651-2227.1984.tb09962.x. [DOI] [PubMed] [Google Scholar]
  31. Lopez E. L., Diaz M., Grinstein S., Devoto S., Mendilaharzu F., Murray B. E., Ashkenazi S., Rubeglio E., Woloj M., Vasquez M. Hemolytic uremic syndrome and diarrhea in Argentine children: the role of Shiga-like toxins. J Infect Dis. 1989 Sep;160(3):469–475. doi: 10.1093/infdis/160.3.469. [DOI] [PubMed] [Google Scholar]
  32. Louise C. B., Obrig T. G. Specific interaction of Escherichia coli O157:H7-derived Shiga-like toxin II with human renal endothelial cells. J Infect Dis. 1995 Nov;172(5):1397–1401. doi: 10.1093/infdis/172.5.1397. [DOI] [PubMed] [Google Scholar]
  33. MacLeod D. L., Gyles C. L. Immunization of pigs with a purified Shiga-like toxin II variant toxoid. Vet Microbiol. 1991 Nov;29(3-4):309–318. doi: 10.1016/0378-1135(91)90138-6. [DOI] [PubMed] [Google Scholar]
  34. O'Brien A. D., LaVeck G. D., Thompson M. R., Formal S. B. Production of Shigella dysenteriae type 1-like cytotoxin by Escherichia coli. J Infect Dis. 1982 Dec;146(6):763–769. doi: 10.1093/infdis/146.6.763. [DOI] [PubMed] [Google Scholar]
  35. O'Brien A. D., Tesh V. L., Donohue-Rolfe A., Jackson M. P., Olsnes S., Sandvig K., Lindberg A. A., Keusch G. T. Shiga toxin: biochemistry, genetics, mode of action, and role in pathogenesis. Curr Top Microbiol Immunol. 1992;180:65–94. doi: 10.1007/978-3-642-77238-2_4. [DOI] [PubMed] [Google Scholar]
  36. Obrig T. G., Del Vecchio P. J., Brown J. E., Moran T. P., Rowland B. M., Judge T. K., Rothman S. W. Direct cytotoxic action of Shiga toxin on human vascular endothelial cells. Infect Immun. 1988 Sep;56(9):2373–2378. doi: 10.1128/iai.56.9.2373-2378.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Reymond D., Karmali M. A., Clarke I., Winkler M., Petric M. Comparison of the western blot assay with the neutralizing-antibody and enzyme-linked immunosorbent assays for measuring antibody to verocytotoxin 1. J Clin Microbiol. 1997 Mar;35(3):609–613. doi: 10.1128/jcm.35.3.609-613.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Richardson S. E., Karmali M. A., Becker L. E., Smith C. R. The histopathology of the hemolytic uremic syndrome associated with verocytotoxin-producing Escherichia coli infections. Hum Pathol. 1988 Sep;19(9):1102–1108. doi: 10.1016/s0046-8177(88)80093-5. [DOI] [PubMed] [Google Scholar]
  39. Richardson S. E., Rotman T. A., Jay V., Smith C. R., Becker L. E., Petric M., Olivieri N. F., Karmali M. A. Experimental verocytotoxemia in rabbits. Infect Immun. 1992 Oct;60(10):4154–4167. doi: 10.1128/iai.60.10.4154-4167.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Riley L. W., Remis R. S., Helgerson S. D., McGee H. B., Wells J. G., Davis B. R., Hebert R. J., Olcott E. S., Johnson L. M., Hargrett N. T. Hemorrhagic colitis associated with a rare Escherichia coli serotype. N Engl J Med. 1983 Mar 24;308(12):681–685. doi: 10.1056/NEJM198303243081203. [DOI] [PubMed] [Google Scholar]
  41. Rowe P. C., Orrbine E., Wells G. A., McLaine P. N. Epidemiology of hemolytic-uremic syndrome in Canadian children from 1986 to 1988. The Canadian Pediatric Kidney Disease Reference Centre. J Pediatr. 1991 Aug;119(2):218–224. doi: 10.1016/s0022-3476(05)80730-9. [DOI] [PubMed] [Google Scholar]
  42. Scotland S. M., Smith H. R., Rowe B. Two distinct toxins active on Vero cells from Escherichia coli O157. Lancet. 1985 Oct 19;2(8460):885–886. doi: 10.1016/s0140-6736(85)90146-1. [DOI] [PubMed] [Google Scholar]
  43. Siegler R. L., Milligan M. K., Burningham T. H., Christofferson R. D., Chang S. Y., Jorde L. B. Long-term outcome and prognostic indicators in the hemolytic-uremic syndrome. J Pediatr. 1991 Feb;118(2):195–200. doi: 10.1016/s0022-3476(05)80482-2. [DOI] [PubMed] [Google Scholar]
  44. Strockbine N. A., Marques L. R., Newland J. W., Smith H. W., Holmes R. K., O'Brien A. D. Two toxin-converting phages from Escherichia coli O157:H7 strain 933 encode antigenically distinct toxins with similar biologic activities. Infect Immun. 1986 Jul;53(1):135–140. doi: 10.1128/iai.53.1.135-140.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Thomas A., Smith H. R., Rowe B. Use of digoxigenin-labelled oligonucleotide DNA probes for VT2 and VT2 human variant genes to differentiate Vero cytotoxin-producing Escherichia coli strains of serogroup O157. J Clin Microbiol. 1993 Jul;31(7):1700–1703. doi: 10.1128/jcm.31.7.1700-1703.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Trompeter R. S., Schwartz R., Chantler C., Dillon M. J., Haycock G. B., Kay R., Barratt T. M. Haemolytic-uraemic syndrome: an analysis of prognostic features. Arch Dis Child. 1983 Feb;58(2):101–105. doi: 10.1136/adc.58.2.101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Upadhyaya K., Barwick K., Fishaut M., Kashgarian M., Siegel N. J. The importance of nonrenal involvement in hemolytic-uremic syndrome. Pediatrics. 1980 Jan;65(1):115–120. [PubMed] [Google Scholar]
  48. Wadolkowski E. A., Sung L. M., Burris J. A., Samuel J. E., O'Brien A. D. Acute renal tubular necrosis and death of mice orally infected with Escherichia coli strains that produce Shiga-like toxin type II. Infect Immun. 1990 Dec;58(12):3959–3965. doi: 10.1128/iai.58.12.3959-3965.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Willshaw G. A., Smith H. R., Scotland S. M., Field A. M., Rowe B. Heterogeneity of Escherichia coli phages encoding Vero cytotoxins: comparison of cloned sequences determining VT1 and VT2 and development of specific gene probes. J Gen Microbiol. 1987 May;133(5):1309–1317. doi: 10.1099/00221287-133-5-1309. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES